Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

GlaxoSmithKline (GSK - Analyst Report) recently announced that Aspen Global Inc., a subsidiary of Aspen Pharmacare Holdings Limited, has offered to buy Glaxo’s thrombosis brands. Aspen Pharma has also offered to purchase the related manufacturing site in France, Notre-Dame de Bondeville. The financial terms of the deal were not disclosed.

Glaxo’s thrombosis brands include Arixtra and Fraxiparine. In the first quarter of 2013, Arixtra and Fraxiparine generated sales of £49 million (up 2% from the year-ago quarter) and £52 million (down 16% from the year-ago quarter), respectively. The proposed deal does not include right to the drugs in China, India and Pakistan.  

Glaxo and Aspen Pharma are no strangers to each other. Glaxo holds approximately 18.6% of Aspen Pharma’s shares (as per Aspen Pharma’s 2012 annual report). Both the companies had entered into a number of deals in the past.

Last year, Glaxo divested the majority of its Classic Brands in Australia and non-core over-the-counter (OTC) brands sold in international markets to Aspen Pharma.

We note that Glaxo’s product portfolio was boosted recently with the approvals of two melanoma drugs, Tafinlar (dabrafenib) and Mekinist (trametinib) and chronic obstructive pulmonary disease drug, Breo Ellipta. Moreover, Glaxo boasts of a robust pipeline. A number of pipeline-related news is expected in the coming quarters. We believe that the pipeline at Glaxo must deliver to combat the generic threat faced by the key drugs of the company.

Glaxo carries a Zacks Rank #3 (Hold). Companies that currently look well-positioned include Biogen Idec (BIIB - Analyst Report), Santarus, Inc. and Novo Nordisk (NVO - Analyst Report). While Biogen and Santarus are Zacks Rank #1 (Strong Buy) stock, Novo Nordisk is a Zacks Rank #2 (Buy) stock.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
KNIGHTSBRIDG VLCCF 13.97 +11.40%
MODINE MANUF MOD 16.77 +6.57%
CANADIAN SOL CSIQ 30.92 +5.85%
E*TRADE FINA ETFC 22.68 +5.48%
QUESTCOR PHA QCOR 83.14 +3.83%